Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
2021 · Nature Communications · 373 citations
https://doi.org/10.1038/s41467-021-22958-8
M
Maria Laura De Angelis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
51
Papers
2.0K
Citations
22
h-index
30
i10-index
Maria Laura De Angelis is an academic researcher from Istituto Superiore di Sanità. The author has contributed to research in topics: Cancer Cells and Metastasis & Cancer Genomics and Diagnostics & Digestive system and related health. The author has an h-index of 22, co-authored 44 publications.
ORCID: 0000-0003-4220-8822Papers by this author
worksOrganoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases
2019 · Cell Death and Disease · 157 citations
https://doi.org/10.1038/s41419-019-1453-0
Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer
2015 · Cell Death and Differentiation · 54 citations
https://doi.org/10.1038/cdd.2015.19
COVID-19: a potential driver of immune-mediated breast cancer recurrence?
2020 · Breast Cancer Research · 50 citations
https://doi.org/10.1186/s13058-020-01360-0
A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells
2019 · Journal of Experimental & Clinical Cancer Research · 40 citations
https://doi.org/10.1186/s13046-019-1383-9
A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice
2024 · Journal of Experimental & Clinical Cancer Research · 6 citations
https://doi.org/10.1186/s13046-024-03213-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat